CYP3A4

Cytochrome P450 3A4 · P08684 · CYP3A4 on Sugi Atlas →

3,405,821 patent compounds predicted against CYP3A4, 2,076,233 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fluconazole (SCHEMBL3151)	1.00	16/20
Oleandomycin (SCHEMBL3716)	1.00	12/20
Oleandomycin (SCHEMBL3717)	1.00	12/20
Ergotamine (SCHEMBL1483)	1.00	9/20
Erythromycin Propionate (SCHEMBL3331)	1.00	9/20
Pentachlorophenol (SCHEMBL1492)	0.42	9/20
Erythromycin (SCHEMBL2601)	1.00	8/20
Erythromycin (SCHEMBL2602)	1.00	8/20
Testosterone Propionate (SCHEMBL4044)	1.00	8/20
Testosterone (SCHEMBL4045)	0.85	8/20
Etoposide Phosphate (SCHEMBL3621)	0.83	8/20
Erbulozole (SCHEMBL3824)	0.40	8/20
Megestrol Acetate (SCHEMBL745)	1.00	7/20
Mevastatin (SCHEMBL1116)	1.00	7/20
Lovastatin (SCHEMBL3136)	1.00	7/20
Lovastatin (SCHEMBL3137)	1.00	7/20
Beclomethasone (SCHEMBL3183)	1.00	7/20
Dexamethasone (SCHEMBL3774)	1.00	7/20
Flumethasone (SCHEMBL4046)	1.00	7/20
Clobetasol (SCHEMBL3996)	0.85	7/20

Clinical trials — most relevant to CYP3A4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG	PHASE4	UNKNOWN
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007	PHASE3	COMPLETED
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)	PHASE3	NOT_YET_RECRUITING
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%	PHASE3	COMPLETED
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer	PHASE2	COMPLETED
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers	PHASE1	COMPLETED
Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults	PHASE1	COMPLETED
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics	PHASE1	COMPLETED
A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants	PHASE1	COMPLETED
Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4	PHASE1	COMPLETED
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers	PHASE1	COMPLETED
Drug-Drug Interaction Study of Qualaquin and Midazolam	PHASE1	COMPLETED
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults	PHASE1	COMPLETED
Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers	PHASE1	COMPLETED
Safety Tolerability and Pharmacokinetic of BI 411034	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers	PHASE1	COMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain	nan	UNKNOWN
Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers	nan	COMPLETED
Sensory Evaluation of the Taste of Pediatric Medicines	nan	COMPLETED
Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania	nan	UNKNOWN
Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer	nan	UNKNOWN
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP3A4 binder may also engage these)

Protein	Name	Similarity
CYP3A7	Cytochrome P450 3A7	1.000	landscape →
O18993	—	1.000	O18993 →
P33268	—	1.000	P33268 →
Q64464	—	1.000	Q64464 →
P79401	—	1.000	P79401 →
CYP3A5	Cytochrome P450 3A5	1.000	landscape →
Q29496	—	1.000	Q29496 →
P11707	—	1.000	P11707 →
O09158	—	1.000	O09158 →
Q64481	—	0.999	Q64481 →
P24463	—	0.999	P24463 →
P79102	—	0.999	P79102 →
P05183	—	0.998	P05183 →
Q9PVE8	—	0.998	Q9PVE8 →
Q8AXY5	—	0.998	Q8AXY5 →
P51538	—	0.997	P51538 →
Q64459	—	0.997	Q64459 →
P04800	—	0.995	P04800 →
Q64581	—	0.994	Q64581 →
O70537	—	0.993	O70537 →
Q98T91	—	0.993	Q98T91 →
O42563	—	0.993	O42563 →
Q64406	—	0.992	Q64406 →
Q64417	—	0.992	Q64417 →
Q9JMA7	—	0.991	Q9JMA7 →
Q64148	—	0.990	Q64148 →
CYP3A43	Cytochrome P450 3A43	0.990	landscape →
Q64409	—	0.987	Q64409 →
P20817	—	0.980	P20817 →
P24464	—	0.980	P24464 →